Key facts
- Osteoboost’s last known valuation is $45.0M (Apr 2026).
- It has raised $17.8M across 1 recorded rounds; the latest was Accelerator/Incubator in Jan 2024.
- Notable investors include MedTech Innovator, Springboard Enterprises, Matter (Consulting Services (B2B)), Band of Angels, Good Growth Capital — 20 tracked in total.
- 1 investment vehicle was formed to buy Osteoboost shares in the last 12 months, reporting $600K sold to 10 investors, per SEC Form D filings.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Osteoboost
Funding rounds
1 roundsSecondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy Osteoboost shares, reporting $600K sold to 10 investors. Most recent filing May 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About Osteoboost
Developer of a medical device designed to provide relief from osteopenia. The company offers precise, sensor-calibrated vibration delivery, integrated tracking and reminders, and at-home usability to slow bone density loss in postmenopausal women with osteopenia through a wearable vibration therapy device, enabling patients suffering from bone mass problems to access an effective non-drug intervention.
- Industry
- Therapeutic Devices
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2014
- Employees
- 12
- Website
- osteoboost.com/
- Ownership
- Privately Held (backing)
Osteoboost doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Osteoboost shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Osteoboost in its N-PORT filings yet. We sweep new filings monthly.